NCT00248482 - Imatinib Mesylate After Irinotecan and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2002

Primary Completion Date

April 30, 2005

Study Completion Date

January 31, 2008

Conditions

Lung Cancer

Interventions

DRUG

Cisplatin

Cisplatin 60mg/m2 IV day 1 every 21 days x 4 cycles

DRUG

Gleevec™

Gleevac 400 mg po BID (800mg/day)- fo patients with objective response or stable disease.

DRUG

irinotecan

Irinotecan: 65 mg/m2 IV days 1, 8 every 21 days x 4 cycles

Trial Locations (2)

University of Michigan Comprehensive Cancer Center, Ann Arbor

Barbara Ann Karmanos Cancer Institute, Detroit